Read More

Reported Late Wednesday March 08, Neoleukin Therapeutics Provides Strategic Update And Announces Restructuring And Leadership Transition; Chief Executive Officer Jonathan Drachman, M.D., Will Be Stepping Down After A Short Transition

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has

NLTX

Read More

Reported Late Wednesday March 08, LSI Industries Introduces Strategic Plan Update, 5-Year Financial Targets; “Fast Forward” Strategy To Deliver $800M In Net Sales And $100M Adjusted EBITDA By FY28; Sees FY23 Revenue $490M-$500M Vs $496.88M Est

"Fast Forward" Strategy to Deliver $800 million in Net Sales and $100 million Adjusted EBITDA by FY28 LSI Industries Inc. (NASDAQ:LYTS, ", LSI", or the ", Company", )))) a

LYTS